Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28426487 | 0.98 | L3MBTL1 (0.54) | L3MBTL1SIGMAR1DDB1CRBNGSK3A | |
| Hydrochloric Acid SCHEMBL4768580 | 0.98 | L3MBTL1 (0.54) | L3MBTL1SIGMAR1DDB1CRBNGSK3A | |
| SCHEMBL10765650 | 0.92 | L3MBTL1 (0.59) | L3MBTL1SIGMAR1DDB1CRBNGSK3A | |
| SCHEMBL7996202 | 0.90 | ENPP2 (0.51) | L3MBTL1SIGMAR1DDB1CRBNGSK3A | |
| Trifluoroacetic Acid SCHEMBL28701154 | 0.88 | L3MBTL1 (0.46) | L3MBTL1SIGMAR1DDB1CRBNGSK3A | |
| SCHEMBL7265760 | 0.88 | DDB1 (0.48) | L3MBTL1SIGMAR1DDB1CRBNGSK3A | |
| SCHEMBL931348 | 0.85 | SIGMAR1 (0.49) | L3MBTL1SIGMAR1GSK3AGSK3BKMT2A | |
| Tert-Butyl Formate SCHEMBL27800995 | 0.85 | L3MBTL1 (0.43) | L3MBTL1SIGMAR1DDB1CRBNGSK3A | |
| SCHEMBL4694508 | 0.84 | CYP2C9 (0.67) | SIGMAR1KMT2ACYP2C9CYP2C19MEN1 | |
| SCHEMBL4692001 | 0.84 | MEN1 (0.47) | L3MBTL1SIGMAR1KMT2ACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101892-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-114163437-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-115103841-B | Substituted quinolinone piperazine compounds useful as T cell activators | 百时美施贵宝公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4081513-B1 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| US-11998545-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | CYTOKINETICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2000001702-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1998056771-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | disclosed |
| EP-0444156-A4 | METHOD FOR TREATING VASCULAR DISEASES | — | 1992-12-09 | — | — | EP | disclosed |
| US-5164388-A | Hypotensive agents, treatment of congestive heart failure | ABBOTT LABORATORIES (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0439556-A4 | HETEROCYCLIC PEPTIDE RENIN INHIBITORS | — | 1991-10-30 | — | — | EP | disclosed |
| EP-0444156-A1 | METHOD FOR TREATING VASCULAR DISEASES | ABBOTT LABORATORIES (US) | 1991-09-04 | — | — | EP | disclosed |
| EP-0439556-A1 | HETEROCYCLIC PEPTIDE RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1991-08-07 | — | — | EP | disclosed |
| WO-1990005531-A1 | METHOD FOR TREATING VASCULAR DISEASES | ABBOTT LABORATORIES (US) | 1990-05-31 | — | — | WO | disclosed |
| WO-1990004917-A1 | HETEROCYCLIC PEPTIDE RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1990-05-17 | — | — | WO | disclosed |
| EP-0365992-A1 | Heterocyclic peptide renin inhibitors | ABBOTT LABORATORIES (US) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | L3MBTL1 4526/4885SIGMAR1 2744/4885DDB1 1817/4885 |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | L3MBTL1 2631/4885SIGMAR1 3391/4885DDB1 611/4885 |
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | L3MBTL1 4549/4885SIGMAR1 3382/4885DDB1 1894/4885 |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | NAMPT, NNT, NAPRT | L3MBTL1 3352/4885SIGMAR1 2794/4885DDB1 4756/4885 |
| US-11998545-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | L3MBTL1 1445/4885SIGMAR1 3863/4885DDB1 1519/4885 |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | L3MBTL1 1445/4885SIGMAR1 3863/4885DDB1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.